Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Nov 1;98(9):2008–2017. doi: 10.1172/JCI119005

Contributions of de novo synthesis of fatty acids to total VLDL-triglyceride secretion during prolonged hyperglycemia/hyperinsulinemia in normal man.

A Aarsland 1, D Chinkes 1, R R Wolfe 1
PMCID: PMC507644  PMID: 8903319

Abstract

Triglycerides (TG) are synthesized in the liver principally from two sources of fatty acids (FA): FA synthesized de novo in the liver and preformed FA. We have measured the rate of secretion of de novo synthesized FA and total secretion of FA bound to VLDL-TG in healthy men (n = 5) in the basal state, and after 1 (day 1) and 4 d (day 4) of a hypercaloric carbohydrate diet (approximately 2.5 times energy expenditure) that generated a moderate endogenous hyperinsulinemia (plasma insulin approximately 60 microU/ml). Prolonged carbohydrate hyperalimentation/hyperinsulinemia increased plasma VLDL-TG approximately 10-fold in part due to a 3.4-fold increase in total VLDL-TG secretion rate (basal state = 72+/-23, day 4 = 242+/-78 micromol TG/kg/d). Although the secretion of de novo synthesized FA increased throughout the study (basal state = 1.1+/-0.4, day 1 = 15.9+/-7.9, day 4 = 50.0+/-18.8 micromol TG/ kg/d), the 2.7-fold increase in secretion rate of preformed FA (basal state = 70+/-23, day 4 = 191+/-57 micromol TG/kg/d) quantitatively contributed the most to total VLDL-TG secretion rate. Decreased catabolism of VLDL-TG also contributed to the hypertriglyceridemia as reflected by an approximately fourfold decrease in both fractional turnover rate (basal state = 9.2+/-3.8, day 1 = 2.1+/-0.2, day 4 = 2.1+/-0.3 pools/d) and rate of clearance (basal state = 0.35+/-0.08, day 1 = 0.11+/-0.01, day 4 = 0.09+/-0.01 liter/kg/d) of VLDL-TG. Thus, the primary difference between 1 and 4 d of hyperinsulinemia in conjunction with carbohydrate hyperalimentation is the increase in hepatic secretion of preformed FA into VLDL-TG.

Full Text

The Full Text of this article is available as a PDF (217.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ajie H. O., Connor M. J., Lee W. N., Bassilian S., Bergner E. A., Byerley L. O. In vivo study of the biosynthesis of long-chain fatty acids using deuterated water. Am J Physiol. 1995 Aug;269(2 Pt 1):E247–E252. doi: 10.1152/ajpendo.1995.269.2.E247. [DOI] [PubMed] [Google Scholar]
  2. Baba H., Zhang X. J., Kunkel K., Wolfe R. R. Effect of hepatectomy on glucose metabolism in the dog. Metabolism. 1994 Jun;43(6):670–676. doi: 10.1016/0026-0495(94)90113-9. [DOI] [PubMed] [Google Scholar]
  3. Berthezene F. Hypertriglyceridemia: cause or consequence of insulin resistance? Horm Res. 1992;38(1-2):39–40. doi: 10.1159/000182480. [DOI] [PubMed] [Google Scholar]
  4. Boberg J., Carlson L. A., Freyschuss U. Determination of splanchnic secretion rate of plasma triglycerides and of total and splanchnic turnover of plasma free fatty acids in man. Eur J Clin Invest. 1972 Mar;2(3):123–132. doi: 10.1111/j.1365-2362.1972.tb00580.x. [DOI] [PubMed] [Google Scholar]
  5. Carlson L. A., Böttiger L. E., Ahfeldt P. E. Risk factors for myocardial infarction in the Stockholm prospective study. A 14-year follow-up focussing on the role of plasma triglycerides and cholesterol. Acta Med Scand. 1979;206(5):351–360. [PubMed] [Google Scholar]
  6. Castelli W. P. The triglyceride issue: a view from Framingham. Am Heart J. 1986 Aug;112(2):432–437. doi: 10.1016/0002-8703(86)90296-6. [DOI] [PubMed] [Google Scholar]
  7. Chinkes D. L., Aarsland A., Rosenblatt J., Wolfe R. R. Comparison of mass isotopomer dilution methods used to compute VLDL production in vivo. Am J Physiol. 1996 Aug;271(2 Pt 1):E373–E383. doi: 10.1152/ajpendo.1996.271.2.E373. [DOI] [PubMed] [Google Scholar]
  8. Coppack S. W., Jensen M. D., Miles J. M. In vivo regulation of lipolysis in humans. J Lipid Res. 1994 Feb;35(2):177–193. [PubMed] [Google Scholar]
  9. Cryer P. E. Glucose counterregulation: prevention and correction of hypoglycemia in humans. Am J Physiol. 1993 Feb;264(2 Pt 1):E149–E155. doi: 10.1152/ajpendo.1993.264.2.E149. [DOI] [PubMed] [Google Scholar]
  10. Dagher F. J., Lyons J. H., Finlayson D. C., Shamsai J., Moore F. D. Blood volume measurement: a critical study prediction of normal values: controlled measurement of sequential changes: choice of a bedside method. Adv Surg. 1965;1:69–109. [PubMed] [Google Scholar]
  11. DeFronzo R. A. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 1988 Jun;37(6):667–687. doi: 10.2337/diab.37.6.667. [DOI] [PubMed] [Google Scholar]
  12. Duerden J. M., Bartlett S. M., Gibbons G. F. Long-term maintenance of high rates of very-low-density-lipoprotein secretion in hepatocyte cultures. A model for studying the direct effects of insulin and insulin deficiency in vitro. Biochem J. 1989 Nov 1;263(3):937–943. doi: 10.1042/bj2630937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Durrington P. N., Newton R. S., Weinstein D. B., Steinberg D. Effects of insulin and glucose on very low density lipoprotein triglyceride secretion by cultured rat hepatocytes. J Clin Invest. 1982 Jul;70(1):63–73. doi: 10.1172/JCI110604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Foster D. M., Barrett P. H., Toffolo G., Beltz W. F., Cobelli C. Estimating the fractional synthetic rate of plasma apolipoproteins and lipids from stable isotope data. J Lipid Res. 1993 Dec;34(12):2193–2205. [PubMed] [Google Scholar]
  15. Fukuda N., Ontko J. A. Interactions between fatty acid synthesis, oxidation, and esterification in the production of triglyceride-rich lipoproteins by the liver. J Lipid Res. 1984 Aug;25(8):831–842. [PubMed] [Google Scholar]
  16. Gibbons G. F., Burnham F. J. Effect of nutritional state on the utilization of fatty acids for hepatitic triacylglycerol synthesis and secretion as very-low-density lipoprotein. Biochem J. 1991 Apr 1;275(Pt 1):87–92. doi: 10.1042/bj2750087. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Gibbons G. F. Insulin, diabetes and hepatic very-low-density lipoprotein metabolism. Biochem Soc Trans. 1989 Feb;17(1):49–51. doi: 10.1042/bst0170049. [DOI] [PubMed] [Google Scholar]
  18. Gibbons G. F., Wiggins D. Intracellular triacylglycerol lipase: its role in the assembly of hepatic very-low-density lipoprotein (VLDL). Adv Enzyme Regul. 1995;35:179–198. doi: 10.1016/0065-2571(94)00006-o. [DOI] [PubMed] [Google Scholar]
  19. Grundy S. M., Mok H. Y., Zech L., Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res. 1981 Jan;22(1):24–36. [PubMed] [Google Scholar]
  20. Grundy S. M., Mok H. Y., Zech L., Steinberg D., Berman M. Transport of very low density lipoprotein triglycerides in varying degrees of obesity and hypertriglyceridemia. J Clin Invest. 1979 Jun;63(6):1274–1283. doi: 10.1172/JCI109422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. HAVEL R. J., EDER H. A., BRAGDON J. H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955 Sep;34(9):1345–1353. doi: 10.1172/JCI103182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Harris W. S., Connor W. E., Illingworth D. R., Rothrock D. W., Foster D. M. Effects of fish oil on VLDL triglyceride kinetics in humans. J Lipid Res. 1990 Sep;31(9):1549–1558. [PubMed] [Google Scholar]
  23. Havel R. J., Kane J. P., Balasse E. O., Segel N., Basso L. V. Splanchnic metabolism of free fatty acids and production of triglycerides of very low density lipoproteins in normotriglyceridemic and hypertriglyceridemic humans. J Clin Invest. 1970 Nov;49(11):2017–2035. doi: 10.1172/JCI106422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Hellerstein M. K., Christiansen M., Kaempfer S., Kletke C., Wu K., Reid J. S., Mulligan K., Hellerstein N. S., Shackleton C. H. Measurement of de novo hepatic lipogenesis in humans using stable isotopes. J Clin Invest. 1991 May;87(5):1841–1852. doi: 10.1172/JCI115206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Hellerstein M. K., Kletke C., Kaempfer S., Wu K., Shackleton C. H. Use of mass isotopomer distributions in secreted lipids to sample lipogenic acetyl-CoA pool in vivo in humans. Am J Physiol. 1991 Oct;261(4 Pt 1):E479–E486. doi: 10.1152/ajpendo.1991.261.4.E479. [DOI] [PubMed] [Google Scholar]
  26. Hellerstein M. K., Neese R. A. Mass isotopomer distribution analysis: a technique for measuring biosynthesis and turnover of polymers. Am J Physiol. 1992 Nov;263(5 Pt 1):E988–1001. doi: 10.1152/ajpendo.1992.263.5.E988. [DOI] [PubMed] [Google Scholar]
  27. Howard B. V. Lipoprotein metabolism in diabetes mellitus. J Lipid Res. 1987 Jun;28(6):613–628. [PubMed] [Google Scholar]
  28. Kazumi T., Vranic M., Steiner G. Triglyceride kinetics: effects of dietary glucose, sucrose, or fructose alone or with hyperinsulinemia. Am J Physiol. 1986 Mar;250(3 Pt 1):E325–E330. doi: 10.1152/ajpendo.1986.250.3.E325. [DOI] [PubMed] [Google Scholar]
  29. Kelleher J. K., Masterson T. M. Model equations for condensation biosynthesis using stable isotopes and radioisotopes. Am J Physiol. 1992 Jan;262(1 Pt 1):E118–E125. doi: 10.1152/ajpendo.1992.262.1.E118. [DOI] [PubMed] [Google Scholar]
  30. Kissebah A. H., Alfarsi S., Adams P. W. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in man: normolipemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia. Metabolism. 1981 Sep;30(9):856–868. doi: 10.1016/0026-0495(81)90064-0. [DOI] [PubMed] [Google Scholar]
  31. Kissebah A. H., Alfarsi S., Evans D. J., Adams P. W. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus. Diabetes. 1982 Mar;31(3):217–225. doi: 10.2337/diab.31.3.217. [DOI] [PubMed] [Google Scholar]
  32. Lee W. N., Bassilian S., Guo Z., Schoeller D., Edmond J., Bergner E. A., Byerley L. O. Measurement of fractional lipid synthesis using deuterated water (2H2O) and mass isotopomer analysis. Am J Physiol. 1994 Mar;266(3 Pt 1):E372–E383. doi: 10.1152/ajpendo.1994.266.3.E372. [DOI] [PubMed] [Google Scholar]
  33. Lewis G. F., Uffelman K. D., Szeto L. W., Steiner G. Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes. 1993 Jun;42(6):833–842. doi: 10.2337/diab.42.6.833. [DOI] [PubMed] [Google Scholar]
  34. Lewis G. F., Uffelman K. D., Szeto L. W., Weller B., Steiner G. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest. 1995 Jan;95(1):158–166. doi: 10.1172/JCI117633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. McGowan M. W., Artiss J. D., Strandbergh D. R., Zak B. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem. 1983 Mar;29(3):538–542. [PubMed] [Google Scholar]
  36. McGuire E. A., Helderman J. H., Tobin J. D., Andres R., Berman M. Effects of arterial versus venous sampling on analysis of glucose kinetics in man. J Appl Physiol. 1976 Oct;41(4):565–573. doi: 10.1152/jappl.1976.41.4.565. [DOI] [PubMed] [Google Scholar]
  37. Newsholme E. A., Taylor K. Glycerol kinase activities in muscles from vertebrates and invertebrates. Biochem J. 1969 May;112(4):465–474. doi: 10.1042/bj1120465. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Radziuk J., Inculet R. The effects of ingested and intravenous glucose on forearm uptake of glucose and glucogenic substrate in normal man. Diabetes. 1983 Nov;32(11):977–981. doi: 10.2337/diab.32.11.977. [DOI] [PubMed] [Google Scholar]
  39. Reaven G. M., Chen Y. D. Role of insulin in regulation of lipoprotein metabolism in diabetes. Diabetes Metab Rev. 1988 Nov;4(7):639–652. doi: 10.1002/dmr.5610040703. [DOI] [PubMed] [Google Scholar]
  40. Reaven G. M. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med. 1993;44:121–131. doi: 10.1146/annurev.me.44.020193.001005. [DOI] [PubMed] [Google Scholar]
  41. Shumak S. L., Zinman B., Zuniga-Guarjardo S., Poapst M., Steiner G. Triglyceride-rich lipoprotein metabolism during acute hyperinsulinemia in hypertriglyceridemic humans. Metabolism. 1988 May;37(5):461–466. doi: 10.1016/0026-0495(88)90047-9. [DOI] [PubMed] [Google Scholar]
  42. Steiner G. Diabetes and atherosclerosis: an overview. Diabetes. 1981;30(Suppl 2):1–7. doi: 10.2337/diab.30.2.s1. [DOI] [PubMed] [Google Scholar]
  43. Steiner G. Hyperinsulinemia and VLDL kinetics. Adv Exp Med Biol. 1993;334:287–294. doi: 10.1007/978-1-4615-2910-1_22. [DOI] [PubMed] [Google Scholar]
  44. Steiner G., Reardon M. F. A new model of human VLDL metabolism based on simultaneous studies of its APOB and triglyceride. Metabolism. 1983 Apr;32(4):342–347. doi: 10.1016/0026-0495(83)90041-0. [DOI] [PubMed] [Google Scholar]
  45. Taskinen M. R. Hyperinsulinism and dyslipidemias as coronary heart disease risk factors in NIDDM. Adv Exp Med Biol. 1993;334:295–301. doi: 10.1007/978-1-4615-2910-1_23. [DOI] [PubMed] [Google Scholar]
  46. Taskinen M. R. Lipoprotein lipase in diabetes. Diabetes Metab Rev. 1987 Apr;3(2):551–570. doi: 10.1002/dmr.5610030208. [DOI] [PubMed] [Google Scholar]
  47. Taskinen M. R., Packard C. J., Shepherd J. Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM. Diabetes. 1990 Sep;39(9):1017–1027. doi: 10.2337/diab.39.9.1017. [DOI] [PubMed] [Google Scholar]
  48. Vogelberg K. H., Gries F. A., Moschinski D. Hepatic production of VLDL-triglycerides. Dependence of portal substrate and insulin concentration. Horm Metab Res. 1980 Dec;12(12):688–694. doi: 10.1055/s-2007-999233. [DOI] [PubMed] [Google Scholar]
  49. Wasserman D. H., Lacy D. B., Goldstein R. E., Williams P. E., Cherrington A. D. Exercise-induced fall in insulin and increase in fat metabolism during prolonged muscular work. Diabetes. 1989 Apr;38(4):484–490. doi: 10.2337/diab.38.4.484. [DOI] [PubMed] [Google Scholar]
  50. Wolfe R. R., Allsop J. R., Burke J. F. Glucose metabolism in man: responses to intravenous glucose infusion. Metabolism. 1979 Mar;28(3):210–220. doi: 10.1016/0026-0495(79)90066-0. [DOI] [PubMed] [Google Scholar]
  51. Wolfe R. R., O'Donnell T. F., Jr, Stone M. D., Richmand D. A., Burke J. F. Investigation of factors determining the optimal glucose infusion rate in total parenteral nutrition. Metabolism. 1980 Sep;29(9):892–900. doi: 10.1016/0026-0495(80)90130-4. [DOI] [PubMed] [Google Scholar]
  52. Wolfe R. R., Peters E. J. Lipolytic response to glucose infusion in human subjects. Am J Physiol. 1987 Feb;252(2 Pt 1):E218–E223. doi: 10.1152/ajpendo.1987.252.2.E218. [DOI] [PubMed] [Google Scholar]
  53. Wolfe R. R., Shaw J. H., Durkot M. J. Effect of sepsis on VLDL kinetics: responses in basal state and during glucose infusion. Am J Physiol. 1985 Jun;248(6 Pt 1):E732–E740. doi: 10.1152/ajpendo.1985.248.6.E732. [DOI] [PubMed] [Google Scholar]
  54. Woodside W. F., Heimberg M. Effects of anti-insulin serum, insulin, and glucose on output of triglycerides and on ketogenesis by the perfused rat liver. J Biol Chem. 1976 Jan 10;251(1):13–23. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES